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I n t r o d u c t i o n
Sarcoptic mange in animals, which is caused by the Sarcoptes 
scabiei mite (1), is still a problem in most parts of the world (2). 
Although mites are largely a host-specific species in their natural 
range, there are reports of S. scabiei infesting diverse hosts, includ-
ing more than 100 species of mammals, such as dogs, cats, rabbits, 
ovines, bovines, raccoons, and humans (2,3). Sarcoptes scabiei is a 
permanent obligate ectoparasite that lives and reproduces in the 
epidermis (4), most notably in sparse hair regions.
Infestations of S. scabiei var. canis, which causes sarcoptic mange 
in dogs, are not seasonal and have no age, breed, or sexual preva-
lence (5). However, animals enduring poor conditions, such as stress, 
overpopulation, poor nutrition, or immunosuppression, seem to 
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A b s t r a c t
Sarcoptic mange is a pruritic, contagious, ectoparasitic skin disease that affects mammals, including the domestic dog. The 
objective of this study was to evaluate and compare the efficacy of afoxolaner plus milbemycin oxime (NexGard Spectra) and 
afoxolaner alone (NexGard) as treatments for sarcoptic mange in naturally infested dogs. A total of 142 dogs naturally infested 
with Sarcoptes scabiei was evaluated. The dogs were diagnosed by microscopic examinations of skin scrapings. The dogs were 
divided into 2 groups: 96 dogs were treated with a combined dosage of 2.50 to 5.36 mg/kg body weight (BW) of afoxolaner and 
0.50 to 1.07 mg/kg BW of milbemycin oxime and 46 dogs were treated with 2.50 mg/kg BW of afoxolaner alone. The presence 
or absence of pruritus and lesions were evaluated using an analogous scale on days 7, 14, 21, 28, and 56 after receiving the 
treatment. Data obtained were analyzed by Student’s t-test (P # 0.05). The single oral treatment of afoxolaner plus milbemycin 
oxime resulted in a significant reduction in pruritus of 87.4% at 28 d after treatment (P # 0.05). Resolution of the lesions after 
treatment was variable, with a significant decrease (P # 0.05) observed within the first 14 d, although this parameter continued 
to improve until the end of the study on day 28, when a decrease of 96% was observed. By the end of the study, a single dose of 
either the afoxolaner alone or the afoxolaner combined with milbemycin oxime was effective in significantly reducing the signs 
associated with sarcoptic mange during a 56-day evaluation period.
R é s u m é
La gale sarcoptique est une maladie cutanée pruritique et contagieuse causée par un ectoparasite qui affecte les mammifères, incluant le chien 
domestique. L’objectif de la présente étude était d’évaluer et de comparer l’efficacité d’afoxolaner plus oxime de milbemycine (NexGard Spectra) 
et l’afoxolaner seul (NexGard) comme traitement pour la gale sarcoptique chez des chiens naturellement infestés. Un total de 142 chiens 
naturellement infestés avec Sarcoptes scabei furent évalués. Les chiens étaient diagnostiqués par examen microscopique de grattages 
cutanés. Les chiens furent divisés en deux groupes : 96 chiens furent traités avec un dosage combiné de 2,50 à 5,36 mg/kg de poids corporel 
(BW) d’afoxolaner et de 0,50 à 1,07 mg/kg BW d’oxime de milbemycine et 46 chiens furent traités avec 2,50 mg/kg BW d’afoxolaner seul. La 
présence ou l’absence de prurit et de lésions furent évaluées en utilisant une échelle analogue aux jours 7, 14 21, 28 et 56 après avoir reçu le 
traitement. Les données obtenues furent analysées à l’aide d’un test de t de Student (P # 0,05). Le traitement unique avec de l’afloxolaner 
plus oxime de milbemycine a résulté en une réduction significative du prurit de 87,4 % au jour 28 après le traitement (P # 0,05). Une 
résolution des lésions après le traitement était variable, avec une diminution significative (P # 0,05) étant observée au cours des 14 premiers 
jours, bien que ce paramètre continua de s’améliorer jusqu’à la fin de l’étude au jour 28, alors qu’une diminution de 96 % fut observée. À 
la fin de cette étude, une dose unique de soit de l’afoxolaner seul ou une combinaison afoxolaner-oxime de milbemycie était efficace à réduire 
de manière significative les signes associés avec la galle sarcoptique durant une période d’évaluation de 56 jours.
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be most susceptible to the disease (6). Sarcoptic mange is a pruritic 
disease with lesions that usually begin in less dense regions of the 
integument, such as the periocular skin, ear margins, and elbows (7). 
It can manifest itself via alopecia, scales, scabs, papules and, less 
often, lichenification and melanoderma (8). Skin damage can occur 
due to self-trauma secondary to pruritus (9), which allows mites to 
spread to an increasing proportion of the epidermis (7). Secondary 
skin infections are also common (9).
Diagnosis is based on clinical history, with a sudden onset of 
intense itching in one or more localized areas (10). Diagnosis is 
definitive with microscopic examination of skin scrapings revealing 
mites, eggs, and the remains of feces (11). As the sensitivity of this 
test has been shown to be less than 50% (12), the response to treat-
ment is also considered a diagnostic method (13).
Therapeutic options for controlling sarcoptic mange consist of 
topical products such as selamectin (8) or moxidectin with imi-
dacloprid (14). Medicated baths are usually part of the therapy to 
control scabies as they reduce the presence of scabs and dead mites 
and shorten treatment times (8). Subcutaneous ivermectin has also 
shown a variable response (15,8,16), although some dog breeds show 
adverse effects (17). A recent therapeutic option for sarcoptic mange 
in some areas is oral treatment with isoxazolines (18,5), which have 
demonstrated potent acaricidal and insecticidal activity through a 
mechanism of binding to neuronal chloride channels activated by 
gamma-Aminobutyric acid (GABA) and glutamate (19).
Afoxolaner, a molecule belonging to the isoxazoline class, has 
proven to be effective against S. scabiei, showing complete para-
sitological cure in dogs with sarcoptic mange after monthly oral 
treatment at the minimum effective dose of 2.50 mg/kg body 
weight (BW) (20). A chewable formulation that combines afoxolaner 
with milbemycin oxime, a macrocyclic lactone, has recently been 
registered to treat and control infestations of fleas, ticks, and infec-
tions with intestinal nematodes (21). Although milbemycin oxime 
is nematocidal, it has also been used in the treatment of sarcoptic 
mange and has proven useful in therapeutic management of scabies 
in dogs (22), without adverse reactions in dogs considered poten-
tially sensitive to ivermectin (23). Therefore, the present study was 
designed to compare the efficacy of afoxolaner plus milbemycin 
oxime and afoxolaner alone as a treatment in dogs with natural 
infestation of S. scabiei.
M a t e r i a l s  a n d  m e t h o d s
This study protocol was approved by the Ethics Committee of 
the Amecameca University Center of the Autonomous University of 
the State of Mexico (UAEM142), client-owned dogs from the State 
of Mexico, Mexico City, and Guadalajara, Mexico were included. 
The inclusion criteria were dogs of any age, breed, and gender that 
were positive for S. scabiei on microscopic study and with the prior 
approval of the owner by a letter of consent. The dogs were consid-
ered positive when the skin microscopy showed at least 1 infective 
form of S. scabiei, which was identified according to the morphology 
of the American Association of Veterinary Parasitologists (AAVP) 
guide (24), and with characteristic signs of sarcoptic mange.
During the treatment period, the dogs remained in standard 
accommodation and were fed a standard diet. All dogs were evalu-
ated on days 1, 7, 14, 21, 28, and 56. The evaluations were made by 
microscopy, with samples obtained by scraping, and by observing 
clinical signs of sarcoptic mange, such as erythema, comedones, 
follicular papules, pustules, scales, scabs, and alopecia. Areas such 
as the face, head, neck, sternum, chest, groin, abdomen, back, sides, 
front, rear end, perianal, perigenital, and tail were evaluated and 
each sign assigned a value of 0 (none), 1 (light), 3 (moderate), and 
6 (severe), with a maximum value of 864 points. The level of pruritus 
was evaluated using a scale of 0 to 10, depending on its intensity. 
The evaluations of the dermatologic and pruritic lesions were carried 
out by the same person every day, for each dog.
A total of 142 dogs took part in this study. The dogs were divided 
into 2 groups. Group 1 consisted of 96 dogs and group 2 consisted 
of 46 dogs. On day 1 (time of positive skin scrapings), the dogs in 
group 1 were treated orally with a combination of 2.50 to 5.36 mg/kg 
BW of afoxolaner and 0.50 to 1.07 mg/kg BW of milbemycin oxime 
in a chewable tablet (NexGard Spectra; Mérial, Lyon, France). Dogs 
in group 2 were treated with 2.50 mg/kg BW of afoxolaner alone 
(NexGard; Mérial). For both groups, the tablets were adminis-
tered directly into the mouth 10 min after eating. Skin scrapings 
were repeated on days 7, 14, 21, 28, and 56 and the presence or 
absence of live mites was recorded. The qualification of derma-
tologic lesions and evaluation of pruritus were repeated on these 
same days.
Data analysis
The data were captured in a database for further analysis. At the 
first statistical moment, the distribution of the data was determined 
and did not present a normal distribution. The data were analyzed. 
and the information on the variables of pruritus and lesions during 
the week were analyzed by Tukey’s studentized range test with an 
alpha of 0.05.
Re s u l t s
The comparison of means of the pruritus level was done on days 1, 
7, 14, 21, 28, and 56, as shown in Table I. While the pruritus scale 
was statistically equal at the beginning of the study, by day 7 there 
was a significant difference between the 2 treatments, showing a 
greater decrease in the pruritus level with the combined afoxolaner 
and milbemycin oxime treatment (group 1). On day 14 and 21, the 
results were the same and by day 28 the pruritus level had decreased 
to zero, which was a significant difference from afoxolaner (group 2). 
On day 56 post-treatment, however, both groups reached 0 on the 
pruritus scale.
The score of the lesions showed a significant difference from day 1, 
with a higher value in the dogs given afoxolaner and milbemycin 
oxime (group 1) on day 7 (Table II). The afoxolaner and milbemycin 
oxime treatment subsequently presented a notable difference and 
a greater decrease in the lesions despite the fact that the mean was 
higher at the beginning of the treatment in dogs treated with afoxo-
laner alone (group 2). Subsequently, on days 14, 21, and 28, there 
was also a significant difference between treatments, with a lower 
score in dogs given afoxolaner and milbemycin oxime (group 1). 
However, on day 56, which was the last day of testing, the lesion 
score of both groups had decreased to 0.
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D i s c u s s i o n
According to the results of the present study, oral administra-
tion of 2.50 to 5.36 mg/kg BW of afoxolaner combined with 0.50 to 
1.07 mg/kg BW of milbemycin oxime (NexGard Spectra) signifi-
cantly reduces the severity of the lesions and reduces the pruritus 
level to 0 in dogs naturally infested with S. scabiei by 28 d. The 
variability of results in the 142 dogs evaluated in this study dem-
onstrates that sarcoptic mange has no predilection for breed, sex, 
or age (18,25).
The clinical resolution of pruritus and skin lesions associated with 
a decrease in the number of mites has previously been reported for 
products such as selamectin (26), imidacloprid/moxidectin (27,28), 
fipronil (25), amitraz/fipronil/S-methoprene (29), and topical 
fluralaner (5). Ivermectin is the most used treatment due to its 
convenience, low cost, and relative safety in dogs, except in some 
breeds (30), although cases have been reported that are refractory 
to treatment (25).
In the present study, the intensity of pruritus decreased signifi-
cantly over the course of 2 weeks, indicating that afoxolaner plus 
milbemycin oxime has rapid acaricidal activity. In a previous study, 
afoxolner demonstrated a reduction in pruritus to 0% associated with 
a total eradication of mites at 56 d (20). In the present study, although 
the pruritus level decreased, it continued until day 28 in the dogs 
given afoxolaner alone (group 2). It is therefore possible that the 
dead mites remaining on the skin continue to cause local irritation 
for more than 28 d. Fluralaner has been used in similar studies and 
a decrease of 98% in pruritus was observed on day 28 (3). This was 
similar to what was previously observed on day 60, with 2 monthly 
administrations of sarolaner (18). The results obtained show that 
pruritus was reduced by 87.4%, lower than previously reported 
with other isoxazolines. It is therefore likely that some mites may 
still be alive after a month, requiring a second dose to achieve full 
antiparasitic efficacy.
Milbemycin oxime as a single treatment for sarcoptic mange has 
also shown good results in reducing pruritus after the third weekly 
dose, with no adverse effects observed in dogs considered potentially 
sensitive to ivermectin (23). No adverse effects were observed in this 
study after the administration of the treatment.
The efficacy of afoxolaner plus milbemycin oxime as an acaricide 
was also accompanied by a decrease in the rate of lesions charac-
teristic of sarcoptic mange. Fluralaner was used in a previous study 
and a decrease of 98.92% in the score of the lesions was observed 
on day 28 (3). This is higher than that obtained in the present study, 
in which the decrease was 96% on day 28. This is probably related 
to the higher rate of pruritus until day 28, which could perpetuate 
the damage. In another study with afoxolaner, a decrease of 60% 
was observed in the crust index on day 28 (20). This is similar to 
the results of another study with fluralaner in which a decrease in 
erythematous papules was observed after 28 d and with sarolaner 
where a decrease of scabs, erythema, papules, and alopecia was 
observed on day 60 (18).
The rapid ectoparasiticidal effect from the use of afoxolaner alone 
and afoxolaner plus milbemycin oxime was previously evaluated in 
a field study of sarcoptic mange in dogs, in which both treatments 
resulted in substantial improvement of pruritus, papules, and crusts, 
Table I. Weekly comparison of means of pruritus level in dogs with sarcoptic mange 
treated with 1 dose of afoxolaner (NexGard) or afoxolaner and milbemycin oxime 
(NexGard Spectra).
 Day
 1 7 14 21 28 56
Afoxolaner 7.47a 6.23a 3.43a 1.67a 0.41a 0a
Afoxolaner & milbemycin oxime 6.87a 3.55b 1.01b 0.07b 0b 0a
CV 24.08 29.36 58.83 123.39 290.50 —
MSE 2.89 1.68 1.11 0.53 0.15 —
a,b Means with different letters within a row represent a significant difference (P , 0.05).
CV — Coefficient of variation; MSE — Mean standard error.
Table II. Weekly comparison of means of lesion scores in dogs with sarcoptic mange 
treated with 1 dose of afoxolaner (NexGard) or afoxolaner and milbemycin oxime 
(NexGard Spectra).
 Day
 1 7 14 21 28 56
Afoxolaner 195.0a 138.50a 54.18a 19.39a 4.60a 0a
Afoxolaner & milbemycin oxime 204.6b 71.85b 23.53b 9.67b 2.46b 0a
CV 0 56.82 76.52 95.47 125.00 —
MSE 0 2857.332 748.44 152.08 15.80 —
a,b Means with different letters within a row represent a significant difference (P , 0.05).
CV — Coefficient of variation; MSE — Mean standard error.
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and alopecia and was statistically significant within 1 mo after the 
initial treatment (31).
In the present study, the treatment with afoxolaner combined 
with milbemycin oxime was associated with a significant reduction 
in the scores of the lesions between days 1 and 14. Although there 
were no significant differences between the following days, the 
score continued to decrease during the rest of the study, although 
the 28 d between the treatment and the evaluation of the lesions 
were probably too short to allow complete clinical resolution. It 
has also been observed that the resolution of the alopecia increases 
significantly after day 56 (20). However, the results of the present 
study are consistent with those obtained by Hampel et al (31), with 
both treatments gradually improving the clinical signs in dogs, in 
addition to being a safe treatment against canine sarcoptic mange.
In conclusion, the medication in which nematocide milbemycin 
oxime is added to afoxolaner in order to extend the ectoparasiticidal 
spectrum of afoxolaner demonstrates a slightly more rapid clinical 
resolution of clinical signs in spite of the fact that the milbemycin 
oxime dose is too low. Both afoxolaner alone and the combination 
of afoxolaner with milbemycin oxime in an oral chewable form are 
valuable tools for the treatment of scabies since both show high 
efficacy against canine sarcoptic mange after a monthly dose.
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